The conversation is about the safety of Breezula compared to RU58841 for hair loss treatment. The user believes Breezula is safer but less effective than RU58841.
People are discussing Breezula, a hair loss treatment, with mixed opinions on its value for the cost. Some are interested in it, while others think it's not worth the money.
The conversation concludes that finasteride, a 5α-Reductase inhibitor used for hair loss, does not impair cognition either short-term or long-term. It suggests "brain fog" is not caused by the medication.
The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It also mentions ongoing human trials for hair multiplication/cloning at Yokohama National University, with skepticism about the timeline.
A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.
Celonius discusses hair loss and plans for a FUE Hair Transplant, but worries about how it will look when shaved in the future. Derhab21 suggests going for the transplant and mentions potential future treatments like Breezula and stem cell injections.
The conversation discusses using stemoxydine for hair loss, with OP considering using 1.5 ml daily despite the recommended 6 ml. Some users doubt its effectiveness, while others report positive experiences using similar amounts.
The user is experiencing hair regrowth using oral minoxidil, finasteride, dermastamping, and ketoconazole shampoo. Suggestions include adding pyrilutamide or considering dutasteride instead of finasteride.
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
Users discuss the release of Pyrilutamide 1% outside China and its potential effectiveness compared to 0.5%. They also mention using Minoxidil, Finasteride, and RU58841 for hair loss treatment.
The conversation discusses the anticipation and skepticism around the release of GT20029 for hair loss treatment. The original poster has been using Finasteride and Minoxidil but is hopeful for GT20029, while others express doubts about its timely release and suggest alternatives like KX826 and hair transplants.
The user is frustrated with the delayed delivery of their Pryiltamide order from Koshine. They mention the order was shipped on August 23 but have received no updates since.
FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.
The user discusses their hair regrowth progress over almost three months using a dermaroller, Minoxidil foam, finasteride pills, and biotin gummies. They share before and after pictures to show the improvement.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.
The conversation is about whether taking 0.5mg of finasteride daily is as effective as 1mg for hair regrowth and if there are long-term studies supporting the lower dose. The user is considering the lower dose to save money and reduce concerns about side effects.
GT20029, a new hair loss treatment, shows promising results but only a slight improvement over placebo. People are cautiously optimistic, discussing its potential and combining it with existing treatments like Minoxidil and Finasteride.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
The conversation is about the correct usage of a hair serum containing redensyl, procapil, capixil, and baicapil. The user is seeking advice on the amount to apply and whether washing hair after application is necessary.
Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.
Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.
The conversation discusses the effectiveness of Dutasteride for hair loss, with some users reporting it works better than Finasteride and sharing positive experiences, while others are skeptical due to negative anecdotes. Specific treatments mentioned include Dutasteride and Finasteride.
The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
Kintor is starting a phase III trial for KX-826 combined with minoxidil for hair loss. Opinions vary on the potential success of the treatment, with some skepticism expressed.
A 23-year-old man shared his 4-month hair regrowth progress using 1mg oral finasteride daily, 5% minoxidil with finasteride topical twice a day, multivitamins, microneedling, head massages, and ketoconazole shampoo. He's unsure of his current Norwood scale classification and is asking for help to determine it, with suggestions ranging from NW4 to NW4.5.
The conversation discusses verteporfin as a potential treatment for hair regeneration, which could lead to unlimited hair transplants by healing the donor area. Some users are considering using verteporfin now, while others are hopeful it will be available for future hair transplants.
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
The conversation is about a user sharing their blood test results and questioning if it's okay to start a hair loss treatment with finasteride. Specific treatments mentioned are Minoxidil, finasteride, and RU58841.